DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide.
$9.46-6.24%
报价 2026-11-06
市值
$1.89B
EV
$3.98B
PE (TTM)
–
预期 PE (FY2026)
6.2x
52 周区间距高点 -35.6%
$8.42$14.68
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 1.35 → 1.47（1.1x） | 6.4 |
| FY+32028-12 | 1.0x | 1.35 → 1.60（1.2x） | 5.9 |
毛利率 51% · TTM 收入 $3575M · 基数 EPS 1.35（调整后）
电话会信号
辅助标签Q3 20262026-11-05
下调/撤回指引
指引 下调
信心 3
分析师 3
“We aim to nearly double the MIS sales force by year-end to build on double-digit U.S. growth.”
原文引用（1）
- 下调/撤回指引：we now expect full-year net sales of approximately $3.5 billion versus the range of $3.5 billion-$3.6 billion previously, and adjusted EPS of $1.20-$1.30 from $1.40-$1.50
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| XRAYDENTSPLY SIRONA Inc. | $1.89B | -6.2% | -2.1% | 53% | – | 11.7x | 18.3x | |
| HAEHaemonetics Corporation | $5.46B | -3.4% | +7.0% | 59.8% | 58.9x | 24.8x | 18.9x | |
| CONConcentra Group Holdings Parent, Inc. | $5.38B | +0.2% | +9.0% | 31.7% | 22.9x | 14.2x | 13.0x | |
| ICUIICU Medical, Inc. | $4.3B | +2.7% | -0.8% | 36.4% | 90.1x | 20.0x | 52.4x | |
| BHCBausch Health Companies Inc. | $3.06B | +2.8% | +7.5% | 75% | – | 8.9x | 1.7x | |
| WRBYWarby Parker Inc. | $2.77B | -2.3% | +10.8% | 54.4% | 424.7x | 41.6x | 129.6x | GARP |
| BEAMBeam Therapeutics Inc. | $2.73B | +2.1% | +81.1% | 100% | – | – | – | |
| RXRXRecursion Pharmaceuticals, Inc. | $2.19B | +0.6% | -3.9% | -49.8% | – | – | – | |
| LMATLeMaitre Vascular, Inc. | $1.85B | -3.1% | +13.0% | 71.5% | 42.4x | 28.8x | 24.8x | |
| 同行中位数 | – | – | +8.2% | 57.1% | 58.9x | 22.4x | 21.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $836M | $898M | $880M | $961M | $904M | $936M | $879M | $905M |
| Gross Margin | 53% | 54.9% | 48.5% | 46.1% | 48.8% | 52.4% | 53% | 49.3% |
| Operating Margin | 4.4% | 9.1% | 3.4% | 27.9% | 5.1% | -13.7% | 7.2% | -56.2% |
| Net Income | $-2M | $37M | $-10M | $-146M | $-427M | $-45M | $20M | $-430M |
| Diluted EPS | -0.01 | 0.18 | -0.05 | -0.73 | -2.14 | -0.23 | 0.1 | -2.16 |
| Operating Cash Flow | $32M | $99M | $40M | $101M | $79M | $48M | $7M | $87M |
研究材料
电话会纪要摘要
暂无纪要摘要。